APELLIS PHARMACEUTICAL

Apellis Receives Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU Following Re-Examination

20 Sep 2024 04:00:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 Sep 2024 15:05:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

29 Aug 2024 06:00:00 By Nasdaq GlobeNewswire

Apellis and Sobi Announce Positive Topline Results from Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN

08 Aug 2024 06:00:01 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 Aug 2024 15:05:01 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Reports Second Quarter 2024 Financial Results

01 Aug 2024 06:05:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Host Conference Call on August 1, 2024, to Discuss Second Quarter 2024 Financial Results

18 Jul 2024 06:00:00 By Nasdaq GlobeNewswire

Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting

09 Jul 2024 06:00:00 By Nasdaq GlobeNewswire

Apellis Plans to Seek Re-Examination Following Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU

28 Jun 2024 05:57:12 By Nasdaq GlobeNewswire

SYFOVRE® (pegcetacoplan injection) Preserved Visual Function at 36 Months in GALE Extension Study in Geographic Atrophy (GA)

10 Jun 2024 06:00:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference

05 Jun 2024 06:00:00 By Nasdaq GlobeNewswire

Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress

24 May 2024 09:00:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Refinances Existing Debt with Up to $475 Million Non-Dilutive Credit Facility from Sixth Street

14 May 2024 07:00:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results

07 May 2024 06:05:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Host a Fireside Chat at the Bank of America Securities Healthcare Conference

06 May 2024 06:00:00 By Nasdaq GlobeNewswire

Apellis Announces 11 Oral Presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

01 May 2024 06:00:00 By Nasdaq GlobeNewswire

Apellis Announces Pegcetacoplan MAA Review Has Been Reset to Day 180 of Initial Assessment by European Medicines Agency (EMA)

26 Apr 2024 06:15:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Host Conference Call on May 7, 2024, to Discuss First Quarter 2024 Financial Results

23 Apr 2024 06:00:14 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 Apr 2024 15:05:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Host a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

01 Apr 2024 06:00:00 By Nasdaq GlobeNewswire